Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07203885 | AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment(LEAP) | completed | N/A | 10 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER |
| 1 |
| Oct 30, 2025 |
| clinicaltrials |
| NCT04188678 | Resiliency in Older Adults Undergoing Bone Marrow Transplant(REBOUND) | completed | — | 126 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
| NCT03118466 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 41 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03515512 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT01316250 | Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia | completed | N/A | 13 | American University of Beirut Medical CenterOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04609826 | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)(DHODH) | completed | Phase 1 | 153 | Janssen Research & Development, LLCINDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05153343 | Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | completed | Phase 1 / Phase 2 | 31 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05470140 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | completed | Phase 1 | 9 | Allotera TherapeuticsINDUSTRY | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06389357 | Retun-to-school Adaptation Program for Children With Cancer(web-based) | completed | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06326697 | Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 32 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07188428 | Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment | completed | — | 2,298 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05223920 | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | completed | Phase 2 | 81 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 7 | Sep 22, 2025 | clinicaltrials |
| NCT04182100 | Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | completed | Phase 2 | 29 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04385160 | Myeloproliferative Neoplasms (MPN) and COVID-19(MPN-COVID) | completed | — | 552 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 9 | Sep 15, 2025 | clinicaltrials |
| NCT06734585 | Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant | completed | — | 114 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 6 | Sep 12, 2025 | clinicaltrials |
| NCT04512105 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | completed | Phase 1 | 6 | University of California, IrvineOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06986772 | TGRX-678 Pharmacokinetic Mass Balance | completed | Phase 1 | 6 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07155382 | Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1 | completed | — | 98 | Asan Medical CenterOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07151820 | A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients | completed | — | 2,546 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT02310321 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | completed | Phase 1 / Phase 2 | 97 | Astellas Pharma IncINDUSTRY | 3 | Sep 2, 2025 | clinicaltrials |
| NCT07150793 | A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan | completed | — | 754 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00357565 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | completed | Phase 2 | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06648512 | Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)(EXCYTE-2) | completed | — | 91 | Exscientia AI LimitedINDUSTRY | 3 | Aug 26, 2025 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT01660607 | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | completed | Phase 1 / Phase 2 | 68 | Stanford UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04057040 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | completed | Phase 2 | 70 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT02793544 | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | completed | Phase 2 | 80 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03957915 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia(INA03) | completed | Early Phase 1 | 33 | Institut Paoli-CalmettesOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04994158 | MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis(MASCOT-R) | completed | — | 238 | Royal Free Hospital NHS Foundation TrustOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05419648 | Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)(MonSThr) | completed | — | 68 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05499611 | Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia(COALA) | completed | — | 120 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04621851 | Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation | completed | — | 260 | University of Milano BicoccaOTHER | 4 | Jul 29, 2025 | clinicaltrials |
| NCT01385423 | Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 26 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06659224 | The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma | completed | — | 2,631 | asmaa salama ibrahimOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05444530 | A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | completed | Phase 1 | 14 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 20, 2025 | clinicaltrials |
| NCT05662956 | A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | completed | Phase 2 | 114 | Hematology department of the 920th hospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04589728 | Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | completed | — | 202 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04669210 | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT(PTCyRuxo) | completed | Phase 2 | 128 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04885127 | Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia | completed | N/A | 25 | Stanford UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | completed | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT00674479 | INCB018424 in Patients With Advanced Hematologic Malignancies | completed | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT01290302 | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza | completed | Phase 1 | 38 | American Regent, Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 31, 2025source: clinicaltrials